Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms

Encouraging results have been observed from initial studies evaluating vaccines targeting the novel beta coronavirus which causes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). BNT162b2 (Pfizer- BioNTech) is a nucleoside-modified mRNA that encodes a full-length SARS-CoV-2 Spike (S) protein, a key target of neutralising antibodies, and has demonstrated a 95% reduction of cases in the general population. However, concerns have been raised around the efficacy of these vaccines in immunosuppressed populations, including patients with haematological malignancy.

Author list


Patrick Harrington, 

Hugues de Lavallade, 

Katie J. Doores, 

Amy O’Reilly, 

Jeffrey Seow, 

Carl Graham, 

Thomas Lechmere, 

Deepti Radia, 

Richard Dillon, 

Yogita Shanmugharaj, 

Andreas Espehana, 

Claire Woodley, 

Jamie Saunders, 

Natalia Curto-Garcia, 

Jennifer O’Sullivan, 

Kavita Raj, 

Shahram Kordasti, 

Michael H. Malim, 

Claire N. Harrison & 

Donal P. McLornan 

Novel Coronavirus SARS-CoV-2


Nature - Leukemia